Skip to main content

Table 1 Baseline characteristics of patients treated with BMT and TEVAR

From: Long-term results of type B aortic dissection patients with tumor after endovascular repair or optimal medical therapy: a single—center and retrospective cohort study

Treatment

Overall

OMT

TEVAR

P value

  

N = 13

N = 27

 

Age

64.56 ± 9.93

66.23 ± 10.50

63.74 ± 9.74

0.44

Male gender

36 (90.00%)

11 (84.62%)

25 (92.59%)

0.43

Smoking

8 (20.00%)

3 (23.08%)

5 (18.52%)

0.74

Drinking

3 (7.50%)

1 (7.69%)

2 (7.41%)

0.97

Comorbidities

 Hypertension

28 (70.00%)

8 (61.54%)

20 (74.07%)

0.47

 Diabetes mellitus

5 (12.50%)

2 (15.39%)

3 (11.11%)

0.99

 Coronary artery disease

3 (7.50%)

0 (0.00%)

3 (11.11%)

0.54

 Stroke

2 (5.00%)

1 (7.69%)

1 (3.70%)

0.99

Malignant diseases

0.53

 Prostate cancer

1 (2.50%)

0 (0.00%)

1 (3.70%)

 

 Thyroid cancer

3 (7.50%)

0 (0.00%)

3 (11.11%)

 

 Lung cancer

5 (12.50%)

1 (7.69%)

4 (14.82%)

 

 Pancreatic cancer

3 (7.50%)

1 (7.69%)

2 (7.41%)

 

 Bladder cancer

2 (5.00%)

0 (0.00%)

2 (7.41%)

 

 Gastric cancer

5 (12.50%)

1 (7.69%)

4 (14.82%)

 

 Sarcoma

2 (5.00%)

1 (7.69%)

1 (3.70%)

 

 Nasopharyngeal carcinoma

2 (5.00%)

2 (15.39%)

0 (0.00%)

 

 Cholangiocarcinoma

3 (7.50%)

2 (15.39%)

1 (3.70%)

 

 Rectal cancer

5 (12.50%)

2 (15.39%)

3 (11.11%)

 

 Renal cancer

5 (12.50%)

2 (15.39%)

3 (11.11%)

 

 Liver cancer

4 (10.00%)

1 (7.69%)

3 (11.11%)

 

 Endstage of cancer

4 (10.00%)

2 (15.39%)

2 (7.41%)

0.58

  1. OMT optimal medical treatment, TEVAR thoracic endovascular repair